Showing papers by "Giuseppe Lauria published in 2002"
TL;DR: Pérez-Castrillón et al. as mentioned in this paper reported the use of fluoroquinolones in the treatment of patients with tularemia, and the less virulent form of F. tularensis was the causative microbe.
Abstract: N Engl J Med, Vol. 346, No. 13 · March 28, 2002 · www.nejm.org · 1029 tients have a titer of 1:160 at one week. However, in an outbreak involving type A organisms, that titer would be considered diagnostic of tularemia, because few serologic surveys have been performed in areas where infection with the type A strain is endemic and in persons who have no history of tularemia. Patients who have had type A pneumonitis do have persistent agglutinating-antibody titers for several years and should be immune to reinfection, if they are immunocompetent. Pérez-Castrillón et al. have reported the use of fluoroquinolones in the treatment of patients with tularemia. I was aware of their report and should have acknowledged their work. In their study, the less virulent form of F. tularensis was the causative microbe. Presumably, disease caused by type A organisms will be as responsive as the less virulent form. However, only a few patients with type A disease have been successfully treated.